Supplements

Transvenous diaphragm neurostimulation reduces mechanical ventilation duration and increases weaning success, leading to cost savings and QALY gains in mechanically ventilated patients

Transvenous diaphragm neurostimulation (tDNS) was associated with a 2.8-day reduction in mechanical ventilation duration and a 10.5% increase in weaning success compared to standard of care. This led to projected acute care cost savings of $12,102 and long-term care savings of $11,999, with 0.10-0.68 QALYs gained over a patient's remaining lifetime.

Last updated: Jul 26, 2026•1 RCTs•📖 Read as article →

Evidence Score

Evidence Score44/100
Human RCT★★☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Health-Economic Value of Transvenous Diaphragm Neurostimulation in Ventilator Weaning.

observational

Pietzsch JB, Ryschon AM, Mehta N, Ways JP, Ataya A, Criner GJ, Shrager JB · Critical care medicine (2026)

Participants: N/A
Duration: Acute hospital stay plus lifetime projection
Intervention: Transvenous diaphragm neurostimulation (tDNS) added to standard of care
Outcome: Mechanical ventilation duration, weaning success rate, acute and long-term care costs, quality-adjusted life-years (QALYs)
Effect Size: 2.8-day reduction in ventilation; 10.5% greater weaning success; $12,102 acute cost savings; 0.10-0.68 QALY gain
Population: Mechanically ventilated patients in a U.S. acute hospital setting

Result:

PubMed: 42479503DOI: 10.1097/CCM.0000000000007262

Mechanism Graph

tDNS stimulates the diaphragm via transvenous electrode
↓
Improves respiratory muscle function
↓
Facilitates earlier weaning from mechanical ventilation
↓
Reduces ventilation duration and associated complications, leading to cost savings and QALY gains

Limitations

  • ⚠Exploratory analysis based on a single randomized trial (RESCUE-3) and real-world claims data, not a definitive cost-effectiveness study
  • ⚠Lifetime projection model relies on assumptions that may not reflect real-world long-term outcomes
  • ⚠Therapy cost of tDNS was not included in the base case cost savings calculation

Frequently Asked Questions

What is transvenous diaphragm neurostimulation (tDNS)?▼

tDNS is a technique that uses a transvenous electrode to stimulate the phrenic nerve and diaphragm, aiming to improve respiratory muscle function and facilitate weaning from mechanical ventilation.

How much cost savings does tDNS provide in the acute setting?▼

Under base case assumptions, tDNS was projected to save $12,102 in acute hospital costs due to reduced mechanical ventilation duration.

What are the long-term benefits of tDNS for patients?▼

The study estimated that improved weaning with tDNS could lead to 0.10-0.68 quality-adjusted life-years (QALYs) gained over a patient's remaining lifetime.

Is tDNS cost-effective compared to standard of care?▼

The analysis suggests tDNS may be cost-effective and high-value, but definitive conclusions require future lifetime cost-effectiveness analyses that include the therapy cost.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Pietzsch JB, Ryschon AM, Mehta N, Ways JP, Ataya A, Criner GJ, Shrager JB. "Health-Economic Value of Transvenous Diaphragm Neurostimulation in Ventilator Weaning.." Critical care medicine, 2026. PMID: 42479503 DOI: 10.1097/CCM.0000000000007262
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.